Hematological traits are important clinical parameters. To test the effects of rare and low-frequency coding variants on hematological traits, we analyzed hemoglobin concentration, hematocrit levels, white blood cell (WBC) counts and platelet counts in 31,340 individuals genotyped on an exome array. We identified several missense variants in CXCR2 associated with reduced WBC count (gene-based P = 2.6 × 10 −13 ). In a separate family-based resequencing study, we identified a CXCR2 frameshift mutation in a pedigree with congenital neutropenia that abolished ligand-induced CXCR2 signal transduction and chemotaxis. We also identified missense or splice-site variants in key hematopoiesis regulators (EPO, TFR2, HBB, TUBB1 and SH2B3) associated with blood cell traits. Finally, we were able to detect associations between a rare somatic JAK2 mutation (encoding p.Val617Phe) and platelet count (P = 3.9 × 10 −22 ) as well as hemoglobin concentration (P = 0.002), hematocrit levels (P = 9.5 × 10 −7 ) and WBC count (P = 3.1 × 10 −5 ). In conclusion, exome arrays complement genome-wide association studies in identifying new variants that contribute to complex human traits.
The proliferation and differentiation of hematopoietic progenitor cells into mature blood cells is a tightly regulated process. Erythrocyte, WBC and platelet counts are used in medicine as diagnostic and prognostic biomarkers. Interindividual variation in quantitative blood cell traits is heritable, and genome-wide association studies (GWAS) have implicated hundreds of loci [1] [2] [3] . The development of new genotyping arrays that target protein-coding variation offers new opportunities to assess the role of rare (defined here as having minor allele frequency (MAF) of <0.1%) and low-frequency (0.1% ≤ MAF < 1%) coding variants in human complex trait genetics. We genotyped 6,796 participants from the Montreal Heart Institute (MHI) Biobank and 18,018 women from the Women's Health Initiative (WHI) on the Illumina HumanExome BeadChip and analyzed associations between 183,585 polymorphic variants and 4 blood cell phenotypes: hemoglobin concentration, hematocrit levels, WBC count and platelet count. We carried forward variants in 19 genes (gene-based P < 1 × 10 −4 ) and 42 single markers (P < 1 × 10 −5 ; along with P < 1 × 10 −4 for coding variants in 3 strong candidate genes: PKLR, BUB1B and TUBB1) for validation of our top association results in 6,526 participants from the Study of Health in Pomerania (SHIP) ( Supplementary Table 1 ). We identified six genetic associations for platelet count (TUBB1, SH2B3 and JAK2), hematocrit levels and hemoglobin concentration (EPO and HBB), and WBC count (CXCR2) that met our predetermined exomewide significance threshold (P < 6.8 × 10 −8 for single variants and P < 3.9 × 10 −7 for gene-based tests) (Tables 1 and 2, Supplementary  Figs. 1-3 and Supplementary Tables 2-4) . These findings highlight the role of rare and low-frequency coding variants in complex traits in large cohorts of individuals not selected on the basis of having a hematological disorder.
We found an association between a low-frequency missense variant (MAF = 0.45%) in the erythropoietin gene EPO (rs62483572; p.Asp70Asn), which encodes the main cytokine that controls erythrocyte production, and lower hematocrit levels and hemoglobin concentration ( Fig. 1a and Table 1 ). Carriers of the EPO missense variant had 0.35 g/dl lower hemoglobin concentration and 1% lower hematocrit levels than non-carriers. To our knowledge, the variant encoding p.Asp70Asn is the first naturally occurring EPO coding variant associated with any hematological phenotype. In the mature EPO protein, p.Asp70Asn (amino acid 43 after cleavage of the signal peptide) is part Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits l e t t e r s of the high-affinity receptor-binding site (Supplementary Fig. 4) 4 . Rare gain-of-function coding variants in the erythropoietin receptor gene (EPOR) have been associated with familial erythrocytosis 5 . EPO is located near the gene encoding transferrin receptor 2 (TFR2), a gene that is important for iron transport and hemoglobin production. Noncoding SNPs in the TFR2-EPO region are associated with red blood cell (RBC) phenotypes 3 . Analysis conditioning on the sentinel SNP in TFR2, rs7385804, indicated that the rare missense variant in EPO is independently associated with hematocrit levels and hemoglobin concentration (Fig. 1a) . This conditional analysis also identified a low-frequency 5′ donor splice-site variant of TFR2 (rs139178017) that was independently associated with higher hematocrit levels and hemoglobin concentration ( Fig. 1a and Supplementary Table 2 ). Other TFR2 splice-site variants have been reported in individuals with atypical hemochromatosis (negative for HFE mutation) 6, 7 .
A rare 5′ donor splice-site variant in the β-globin gene (HBB; rs33971440; MAF = 0.02%) was associated with lower hemoglobin concentration and hematocrit levels ( Table 1 and Supplementary Table 2 ). This rare HBB variant was previously identified in Mediterranean individuals with β 0 thalassemia 8 , which may explain why it is present in North American cohorts (MHI and WHI), owing to immigration, but absent from the SHIP cohort from northern Germany.
Using criteria from the World Health Organization to define anemia (hemoglobin concentration of <12 g/dl in women and <13 g/dl in men), we confirmed that the EPO variant encoding p.Asp70Asn was associated with clinical anemia in the combined analysis of the MHI and WHI cohorts (1,866 cases and 22,397 controls; odds ratio (OR) = 1.7; P = 0.008). The rare HBB splice-site variant was likewise strongly associated with clinical anemia (OR = 36.1; P = 1.1 × 10 −5 ). Listed are genes that are exome-wide significant (P < 3.9 × 10 −7 ) or have both strong statistical evidence of association and biological candidacy. The remaining gene-based results are given in supplementary table 4. We analyzed association between rare nonsynonymous (missense, nonsense) and splice-site variants and blood cell traits using the Burden T1 and SKAT gene-based tests. When applicable, we also conditioned on GWAS sentinel SNPs or excluded low-frequency variants strongly associated with the traits. NA, not applicable. a For EPO, SH2B3 and TUBB1, we conditioned, respectively, on rs7385804, rs3184504 and rs6070697. b For EPO, we excluded rs62483572; for HBB, we excluded rs33971440; for CXCR2, we excluded rs61733609; for SH2B3, we excluded rs72650673; and, for TUBB1, we excluded rs41303899.
npg l e t t e r s Mutations in TUBB1 (which encodes a megakaryocyte-specific form of β-tubulin, a microtubule protein involved in pro-platelet production) cause autosomal dominant macrothrombcytopenia in humans (MIM 612901) and Cavalier King Charles Spaniel dogs 9 . We report a new low-frequency TUBB1 missense variant (rs41303899; p.Gly109Glu; MAF = 0.16%) associated with ~33,000 cells/µl lower mean platelet count ( Table 1) . The association between rs41303899 and platelet count was independent of a common TUBB1 missense variant (rs6070697; p.Arg307His; MAF = 18%; Supplementary Table 3 ) previously associated with mean platelet volume (for rs41303899, meta-analysis P = 3.7 × 10 −5 , meta-analysis conditional on rs6070697 P = 2.4 × 10 −4 ).
A somatic JAK2 mutation encoding p.Val617Phe is a key driver of myeloproliferative neoplasms (MPNs) [10] [11] [12] [13] . In our discovery sample, this JAK2 mutation was strongly associated with platelet count (P = 3.9 × 10 −22 ) and was also associated with hematocrit levels (P = 9.5 × 10 −7 ), hemoglobin concentration (P = 0.002) and WBC count (P = 3.1 × 10 −5 ), highlighting the pan-lineage effects of this somatic gain-of-function mutation ( Table 1) . The JAK2 mutation encoding p.Val617Phe was rare in the MHI and WHI cohorts (MAF = 0.05%), consistent with previous frequency estimates obtained by whole-exome sequencing 14 or allele-specific PCR 15 using peripheral blood samples from unselected individuals. Clinical characteristics, serial blood counts and clinical follow-up information obtained for the 19 mutation carriers in the MHI and WHI studies suggest early-stage MPN in these individuals and also exemplify the phenotypic diversity associated with this somatic JAK2 mutation ( Supplementary Table 5 ). Notably, the frequency of the JAK2 variant encoding p.Val617Phe appeared to be tenfold higher in SHIP (MAF = 0.4%) ( Table 1) ; however, this spuriously high frequency resulted from genotype miscalling, as inspection of the genotyping intensity plots did not identify clearly distinguishable clusters ( Supplementary Fig. 5 ). These observations are consistent with both variable sensitivity in the detection of the JAK2 variant encoding p.Val617Phe across genotyping platforms and heterogeneity in allelic burden across individuals 16, 17 . These issues raise a number of complexities to be considered in the decision to return the results of such incidental findings to research participants.
SH2B3 encodes the adaptor protein LNK, which regulates T and B cell development and myelopoiesis 18 . LNK inhibits the JAK2-STAT pathway and other downstream signaling to modulate hematopoietic cytokine receptor signaling 19 . Both somatic and germline mutations in SH2B3 have been reported in individuals with MPNs 20,21 . In addition to confirming the association of a missense SNP (rs3184504; p.Trp262Arg; MAF = 50%) with all four hematological traits (P < 4.0 × 10 −10 ; Supplementary Table 3 ) 1-3 , we identified two independent SH2B3 missense variants associated with higher platelet count (rs148636776, p.Glu395Lys, MAF = 0.04% and rs72650673, p.Glu400Lys, MAF = 0.1%) ( Fig. 1b) . These two variants affect the functional Src homology 2 domain (SH2) that interacts with JAK2 ( Supplementary Fig. 6 ). The variant encoding p.Glu400Lys was previously identified in ~5% of individuals with idiopathic erythrocytosis 22 . However, in our data set, there was no association between the variant encoding p.Glu400Lys or the new missense variant encoding p.Glu395Lys and hematocrit levels or hemoglobin concentration (P > 0.10). The SH2B3 variants encoding p.Glu395Lys and p.Glu400Lys were not associated with RBC count in the MHI Biobank (P > 0.3). Unfortunately, data on RBC count are not available in the WHI study.
In addition to the new associations described above, we confirmed many SNPs previously associated with blood cell traits by GWAS (Supplementary Table 3 ). The only new common variant identified, rs1465788 (MAF = 27%), was located in the 5′ flanking region of ZFP36L1 and was associated with ~3,000 cells/µl lower mean platelet count ( Table 1) . ZFP36L1 encodes a member of a family of mRNA destabilization proteins involved in regulation of the self-renewal and differentiation of hematopoietic cells 23 . The nearest GWAS index SNP for platelet count is rs11627546, which is located 1.1 Mb away and is not in linkage disequilibrium (LD) with rs1465788 (r 2 = 0.003 in Europeans) 2 . According to Encyclopedia of DNA Elements (ENCODE) data from myeloid K562 cells, the rs1465788 variant lies in a nucleosome-depleted region and is in strong LD (r 2 > 0.90 in a ≥7 TFR2-rs139178017 MAF = 0.4% P = 0.0020, P conditional = 9.3 × 10 -4 EPO-rs62483572 MAF = 0.5% P = 3.5 × 10 -7 , P conditional = 1.1 × 10 -6 TFR2-rs7385804 MAF = 36% P = 0.0013 6 -log 10 (P) Figure 1 Association results in the meta-analysis of the MHI and WHI cohorts (n = 24,814) for hematocrit levels at the TFR2-EPO locus on chromosome 7 and for platelet count at the SH2B3 locus on chromosome 12. The x axes correspond to genomic coordinates. (a) For the TFR2-EPO locus and hematocrit levels, we provide association results for each variant in the region before (circles) and after (stars) conditioning on the GWAS sentinel SNP at the locus (rs7385804). (b) For SH2B3 and platelet count, we provide association results without (circles) and with (stars) adjustment for genotypes at the GWAS sentinel SNP rs3184504. In the GWAS row, we represent all markers in LD with the GWAS sentinel SNP (marked by an inverted triangle) on the basis of data from European populations in the 1000 Genomes Project (the size of the circle is proportional to the strength of LD). We added a vertical line connecting the GWAS and ExomeChip rows if GWAS LD proxies were also present on the ExomeChip array. In the ExomeChip row, all markers analyzed in the region are represented as triangles (intronic, intergenic and synonymous variants) or diamonds (missense, nonsense and splice-site variants). Vertical lines connecting the ExomeChip and Freq 0.5 rows represent allele frequencies in the meta-analysis of the MHI and WHI cohorts.
npg l e t t e r s Europeans) with several common variants in the promoter of ZFP36L1 (Supplementary Fig. 7) . Unfortunately, there are no megakaryocyte or platelet expression quantitative trait locus (eQTL) data sets publicly available. Using a large eQTL study of monocytes from 1,490 participants 24 , we were not able to identify eQTLs for ZFP36L1. However, according to analyses performed in lymphoblastoid cell lines 25 , rs1465788 is in LD with rs10873217 (r 2 = 0.38 in Europeans), an eQTL for ZFP36L1. rs1465788 is also located 77 kb downstream of ACTN1, a gene mutated in macrothrombocytopenia (MIM 615193), but is neither in LD with markers near ACTN1 nor an eQTL for ACTN1 expression. rs1465788 or markers in LD with it have been associated by GWAS with autoimmune disorders [26] [27] [28] . Therefore, it is also plausible that the reason for lower platelet count may involve platelet autoantibody formation, which is a common mechanism of thrombocytopenia in adults 29 . Several additional common, low-frequency and rare coding variants did not reach our stringent statistical threshold (Supplementary Tables 2 and 3) but are located in strong candidate genes, have been associated with other hematological traits or are in LD with a sentinel SNP and could thus explain GWAS signals. These findings are detailed further in the Supplementary Note. The associations for rare and low-frequency coding variants described here represent examples where a single rare variant of large effect dominates phenotypic association. We report an instance of a newly identified signal for WBC count in a gene previously undetected through GWAS where the association comprises multiple rare and low-frequency missense variants in CXCR2 (combined gene-based P = 2.6 × 10 −13 ; Table 2 and Supplementary Table 4 ). The gene-based signal is driven mainly by three independent low-frequency CXCR2 missense variants (rs55799208, p.Arg153His; rs10201766, p.Arg236Cys; and rs61733609, p.Arg248Gln), each associated with lower WBC count ( Fig. 2 and Supplementary  Table 6 ; conditional analysis in Table 2 ). The p.Arg153His, p.Arg236Cys and p.Arg248Gln alterations are located within the second and third intracellular loops of CXCR2, which are important for G protein interactions and receptor activation (Supplementary Fig. 8 ) [30] [31] [32] . Moreover, the Ala249 residue adjacent to p.Arg248Gln is important for CXCR2 intracellular signaling and also represents an allosteric binding site for the CXCR2 antagonists currently undergoing clinical trials 33 . Upon CXCR2 binding of the chemokine CXCL2, CXCR2 signaling promotes neutrophil release from the bone marrow, thereby elevating blood neutrophil counts 34 . Accordingly, when we analyzed the association between CXCR2 missense variants and the counts for different WBC subtypes, the strongest association was with neutrophil count ( Supplementary  Table 7 ). Common variants of CXCL2 are associated with WBC, primarily neutrophil, count 35 .
In mice, neutrophils lacking CXCR2 are preferentially retained in the bone marrow 36 Figure 2 Rare and low-frequency missense variants in CXCR2 are associated with lower WBC count. A vertical line represents the mean WBC count for each study. The middle of each color-coded circle corresponds to the mean WBC count for individuals who carry the corresponding missense variant, and the size of the circles is correlated with allele frequency. The three circles in the lower left corner are provided as references and represent variants with the indicated MAF values. For rs2228413 (p.Arg294Gln), there is a participant from MHI who is a homozygote for the rare allele (star). (a) Intracellular ERK1/2 signaling in HeLa cells expressing wild-type or mutant CXCR2 receptor. HeLa cells transfected with constructs encoding wild-type (WT) CXCR2 or CXCR2fs fused to YFP or YFP alone were stimulated with CXCL8 (100 ng/ml), and lysates were collected over the indicated time course to assess the activation of the ERK1/2 pathway (phosphorylated ERK, pERK). Peak phosphorylation after stimulation of wild-type CXCR2 occurred at 5 min, with significant attenuation of activation by 15 min. No activation over baseline was detected in cells expressing CXCR2fs. ERK1/2 activation 5 min after stimulation of endogenous CXCR4 with CXCL12 (100 ng/ml) was used as a positive control (+). The protein abundance of wild-type CXCR2 (WT), CXCR2fs (FS) and the YFP control (Y) detected with antibody to GFP (GFP) in transfected cell lines is shown to the right. (b) Chemotaxis assay results for HeLa cells expressing wild-type CXCR2 or CXCR2fs fused to YFP. Transiently transfected HeLa cells were seeded in the top chambers of modified Boyden chambers, and CXCL8 (100 ng/ml) was added to the medium in the bottom chambers. The chemotactic index (migration in the presence of CXCL8/ migration in the absence of CXCL8) was calculated from the results of assays performed in triplicate. Robust migration was observed in cells expressing the wild-type CXCR2 protein but not in cells expressing the frameshift mutant or in untransfected cells. Overexpression of each construct was confirmed by detecting YFP fluorescence (expressed in relative fluorescence units, RFU) in aliquots of transfected cells (right). *P < 0.02, Student's t test; NS, not significant. Bars representing standard error are shown. l e t t e r s feature of the rare, autosomal dominant WHIM (warts, hypogammaglobulinemia, immunodeficiency, myelokathexis) syndrome 37 . Most individuals with WHIM syndrome have a gain-of-function mutation in the CXCR4 gene 36, 37 . To further support a role for CXCR2 mutations in neutropenia and neutrophil trafficking, we studied a pedigree in which two siblings were affected with myelokathexis ( Supplementary Fig. 9 ) in the absence of other WHIM syndrome features and in which the involvement of CXCR4 was excluded 38 . Sequence analysis of CXCR2 in affected individuals II-2 and II-4 identified a homozygous deletion within the coding sequence (c.968delA) (Supplementary Fig. 9 ). The encoded mutant protein contained a translational frameshift and a premature termination codon after the addition of six novel amino acids (p.His323fs6*, hereinafter referred to as CXCR2fs). We tested the ability of the mutant CXCR2fs receptor to respond to ligand at the level of signal transduction and chemotaxis. Transfected HeLa cells expressing either wild-type CXCR2 or CXCR2fs were stimulated with the ligand CXCL8 over a 15-min time course. The accumulation of serine-phosphorylated extracellular signal-regulated kinases 1 and 2 (ERK1/2) was used to assess the activation of the mitogen-activated protein kinase (MAPK) signaling cascade. Accumulation of phosphorylated ERK1/2 was maximal at the 5-min time point after stimulation of the wild-type CXCR2 receptor, whereas cells expressing CXCR2fs had no detectable response (Fig. 3a) . Consistent with these results, cells expressing wildtype CXCR2 had a robust chemotactic response to CXCL8, whereas cells expressing CXCR2fs did not, supporting the notion that the frameshift mutation caused a loss of receptor function (Fig. 3b) . Together with our population-based results, these family-based and functional data support the concept that CXCR2 regulates neutrophil mobilization from the bone marrow and peripheral neutrophil counts.
Our results clearly demonstrate that rare and low-frequency coding variants contribute to phenotypic variation in human populations. We discovered new missense variants in key regulators of hematopoiesis (EPO, SH2B3 and TUBB1) that have potential implications for diagnostic screening and drug development in a variety of hematological and inflammatory disorders (cytopenias, MPNs, lung disease and stroke). For example, rare SH2B3 mutations may account for additional cases of MPN negative for JAK2 mutation. We also provide further support for the biological role of several molecules in the regulation of hematopoiesis (CXCR2 and ZFP36L1). Collectively, our findings validate exome-wide genotyping in very large samples as an effective tool and complementary approach to GWAS and deep DNA resequencing studies for defining the allelic architecture of complex traits. The association of a collection of rare and low-frequency CXCR2 coding variants with WBC count emphasizes the relevance of gene-based tests as we continue to query even rarer variants for their role in human phenotypic variation.
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oNLINe MeTHods
Study participants and phenotypes. The MHI Biobank is a longitudinal cohort with the aim of recruiting 30,000 patients of the MHI for clinical and genetic research 39 . Participants are recruited from different departments within the MHI and at its affiliated EPIC center (Centre de Médecine Préventive et d' Activité Physique de l'Institut de Cardiologie de Montréal), the largest fitness center in Canada for coronary patients and research in primary and secondary disease prevention. The MHI ethics committee approves the project, and informed consent is obtained from all participants. The MHI cohort collects data by using a 35-page questionnaire administered by a research nurse at baseline, including information of demographics, personal and family medical history, physical activity, diet, tobacco use and medication use, as well as depression and hostility questionnaires. Vital signs (heart rate, blood pressure, weight, height and waist circumference) are obtained by the nurse, and blood, DNA and plasma are collected and stored at the Beaulieu-Saucier Pharmacogenomics Center. The health status of participants is confirmed by the nurse using the hospital's health record for retrospective and prospective follow-up. The database for the cohort is updated frequently with participants' medical information from the hospital's electronic records. A follow-up study questionnaire is administered every 4 years. Blood cell counts and other related phenotypes were automatically generated with the UniCel DxH 800 cellular analysis system from Beckman Coulter.
The WHI is one of the largest (n = 161,808) US studies of women's health. This project was approved by the ethics committee at the Fred Hutchinson Cancer Research Center. The WHI consists of 2 main components: (i) a clinical trial that enrolled 68,132 post-menopausal women aged 50-79 years and randomized them to 1 of 3 placebo-controlled clinical trials of hormone therapy, dietary modification or supplementation with calcium and vitamin D and (ii) an observational study that enrolled 93,676 women of the same age range in a parallel prospective study 40 . Of the women in the WHI cohort who were eligible and consented to genetic research, 18,072 were included in the current study. Samples for blood count were collected at baseline by venipuncture into tubes containing EDTA. Blood counts were performed with automated hematology cell counters and standardized quality assurance procedures. Hemoglobin concentration, hematocrit levels, WBC count and platelet count were the only complete blood count values recorded at data entry during the WHI baseline examination, which was conducted nationwide during 1993-1998.
The Study of Health in Pomerania consists of two independent prospectively collected population-based cohorts in West Pomerania (SHIP and SHIP-TREND), a region in the northeast of Germany, assessing the prevalence and incidence of common population-based diseases and their risk factors. The study followed the recommendations of the Declaration of Helsinki. The study protocol for SHIP was approved by the medical ethics committee of the University of Greifswald. Written informed consent was obtained from each of the study participants. The study design has previously been described in detail 41 . Briefly, a sample from the population aged 20 to 79 years was drawn from population registries. First, the three cities of the region (with 17,076 to 65,977 inhabitants) and the 12 towns (with 1,516 to 3,044 inhabitants) were selected, and 17 of the 97 smaller towns (with fewer than 1,500 inhabitants) were then drawn at random. Second, from each of the selected communities, subjects were drawn at random in proportion to the population size of each community and were stratified by age and sex. Only individuals with German citizenship and main residency in the study area were included.
For SHIP, baseline examinations were carried out from 1997 until 2001, and the sample finally comprised 4,308 participants. Baseline examinations for SHIP-TREND were carried out between 2008 and 2012, with the study finally comprising 4,420 participants. Blood count was measured within 60 min of sample collection. Samples were analyzed at the hospital laboratory in Greifswald with a Coulter Max M analyzer (Coulter Electronics) and with a Coulter T660 analyzer (Coulter Electronics) at the hospital laboratory in Stralsund. Both analyzers were calibrated and maintained according to the manufacturer's instructions. Quality control was performed internally as well as externally by participation in external proficiency testing programs. For this project, data from SHIP-TREND and the first 5-year follow-up of SHIP were included. In all association analyses, the cohort was included as an additional covariate in the model.
Genotyping and quality control steps. We attempted to genotype 10,856 participants from the MHI Biobank on the Illumina ExomeChip array (version Infinium HumanExome v1.0 DNA Analysis BeadChip). Genotyping was performed at the MHI Pharmacogenomics Centre. We initially called genotypes with Illumina GenomeStudio software and, after data quality control, repeated calling of missing genotypes with zCall software 42 . We carried out most quality control steps in PLINK 43 and developed additional custom scripts when needed. We excluded markers with genotyping success rates of <95% and Hardy-Weinberg equilibrium P < 1 × 10 −4 . We excluded samples with genotyping success rates of <95%%, abnormal heterozygosity (inbreeding F values of <−0.2 or >0.1) and extensive low-level identity-bydescent (IBD) sharing with a large number of samples. Genotype concordance calculated from samples genotyped in duplicate or samples also sequenced by the 1000 Genomes Project 44 was >99.99%. To identify population outliers, we used principal-component analysis as implemented in EIGENSOFT 45 and anchored our analysis on continental populations from the 1000 Genomes Project 44 . For this study, we only analyzed individuals of European ancestry. We used GCTA software 46 to detect cryptic relatedness, removing one individual from each pair of samples that shared >18% of their genomes (corresponding to duplicates and first-and second-degree relatives). Our final data set included 9,656 individuals and 136,997 polymorphic markers. Blood cell phenotypes were available for 6,796 MHI Biobank participants ( Supplementary Table 1 ).
DNA samples from the WHI clinical coordinating center were sent to the Broad Institute or the Translational Genomics Research Institute (TGEN) for genotyping and were placed on 96-well plates for processing using the Illumina HumanExome v1.0 SNP array. Genotypes were assigned using GenomeStudio v2010.3. A master file was then created containing all genotypes from the Broad Institute and TGEN. Quality control was performed on this master file using the PLINK and R 47 computing platforms. We excluded markers with a genotyping success rate of less than 99%. We excluded samples with a genotyping success rate of less than 98%. With the resulting sample set, we performed a principal-component analysis as well as an analysis of relatedness using PLINK IBS/IBD functionality. Outlier samples on the principal-component plots were excluded, as were samples that were determined to be contaminated via relatedness analysis (that were apparently related to hundreds of other samples). For each related or duplicate pair of samples, we excluded the sample with the lower call rate. Unexpected duplicate samples were also filtered out to prevent potential sample swaps from entering the analysis. For intentionally duplicated samples, we removed samples with low relatedness estimates, as we expected them to be close to 1. We excluded samples with hemoglobin concentrations greater than 20 g/dl or with a hematocrit (%) to hemoglobin (g/dl) ratio of greater than 5. Samples with WBC count (×10 9 cells/l) greater than 100 were also excluded from the analysis. After quality control, there were 18,072 samples and 166,836 polymorphic markers.
SHIP and SHIP-TREND samples were genotyped using the Illumina ExomeChip array (version Infinium HumanExome v1.0 DNA Analysis BeadChip). Hybridization of genomic DNA was carried out in accordance with the manufacturer's standard recommendations at the Helmholtz Zentrum München. Genotype calling was performed according to ExomeChip quality control standard operating procedure (SOP) version 5. Initial genotypes were determined using GenomeStudio Genotyping Module v1.0 (GenCall algorithm) with the HumanExome-12v1_A manifest file and the standard Illumina cluster file (HumanExome-12v1.egt). Contaminated samples, samples with a call rate of <90% and samples showing extreme heterozygosity, extensive estimated IBD sharing with a large number of samples or mismatch between reported and genotype-determined sex were excluded. Next, calling of missing genotypes was repeated using zCall software version 3.3 with default values. In both cohorts together, 7,366 individuals were successfully genotyped with an average call rate of 99.97%.
Trait modeling and study-level association testing. We used untransformed hemoglobin concentration, hematocrit levels, platelet counts and log 10transformed WBC counts for association testing. Because the analysis of rare variants is particularly sensitive to phenotypic outliers, we winsorized our data such that all individuals with a phenotype below the 0.5 percentile or above the 99.5 percentile of the trait distribution were assigned, respectively, the npg phenotype corresponding to the 0.5 and 99.5 percentile values. In our analysis, phenotype winsorization reduced inflation while maintaining phenotype scale. In the MHI cohort, we used sex, age 2 and the first ten principal components as covariates. In the WHI cohort, we used age and the first two principal components as covariates. We also included a term in the linear model to account for the different WHI substudies that contributed to this project.
We used PLINK 43 to test association between phenotypes and single-variant genotypes (including single-variant conditional analyses) under an additive genetic model. For the gene-based analyses, each cohort ran an analysis with RVtests software 48 . This software calculates a score statistic for each variant and a covariance matrix for markers within sliding windows.
Meta-analysis and statistical significance. We combined single-variant results with Metal using the inverse variance method 49 . For gene-based tests, we combined score test results from RVtests with RareMetal software using default parameters 48 . A priori, we decided to focus exclusively on missense and nonsense variants as well as on variants within donor or acceptor splice sites for these analyses. For each trait, we ran two gene-based tests: a simple burden test with a MAF cutoff of <1% (burden T1) and a sequence kernel association test (SKAT) with a MAF cutoff of <5%.
We defined statistical significance using Bonferroni corrections. For singlevariant analyses, we tested 183,585 DNA sequence variants and 4 phenotypes, yielding α = 0.05/183,585 variants/4 phenotypes = 6.8 × 10 −8 . For gene-based analyses, we tested 15,930 genes (genes with no or only 1 missense, nonsense or splice-site variant were not tested), 4 phenotypes and 2 different statistical tests, yielding α = 0.05/15,930 genes/4 phenotypes/2 tests = 3.9 × 10 −7 .
Functional characterization of CXCR2. A previously described family in which two sisters were affected with isolated myelokathexis 14 was evaluated for mutations in CXCR2. Clinical manifestations in this family included neutropenia without lymphopenia or warts leading to recurrent bacterial infections, including septic thrombophlebitis and subacute bacterial endocarditis. At age 43, one of the siblings was reported to have had >80 infectious episodes 31 . Her younger sister had fewer infectious episodes, which was speculated to result from more robust transient release of neutrophils into the peripheral blood during infection. The family was lost to follow-up and not available for further functional studies on primary cells. Human CXCR2 is encoded by a single exon with multiple upstream noncoding exons giving rise to a number of differentially spliced isoforms. The coding sequence of the gene was amplified on three overlapping PCR fragments and analyzed by automated sequencing. Exonic boundaries were identified using publicly available genomic database information 50 , and primers were designed to amplify coding exons and flanking intronic sequences using Primer3 software 51 . PCR amplicons were sequenced using the ABI3700 automated platform. Confirmatory restriction enzyme analysis was performed using NcoI (New England BioLabs) under standard conditions. IMAGE clone 5752441 containing the full-length CXCR2 ORF was obtained from Invitrogen. The insert was confirmed by sequencing the clone using CXCR2-specific primers. The c.968delA (CXCR2fs), c.
[967C>T]+[969T>G] (p.His323*) and c.
[968delA]+[986insC] (CXCR2fs wild type) mutations were introduced by primers for site-directed mutagenesis and amplified by PfuTurbo (Stratagene). PCR amplification on the resulting clones of the CXCR2 ORF using the IMAGE clone as a template was used to introduce sequence encoding epitopes on the C-terminal tail of the receptor. Primers for amplification contained exogenous restriction sites at their 3′ and 5′ ends and were digested using EcoRI-XhoI (Flag) or EcoRI-SalI (YFP). After digestion with the appropriate enzymes, fragments were ligated in frame upstream of the sequence encoding the 3×Flag epitope in pIRES-3×Flag-hrGFP (Invitrogen) or the YFP full-length coding sequence in pEYFP-N1 (Clontech). The full-length ORFs for Flag-tagged and YFP-fused proteins were verified by sequencing.
HEK293 cells (CRL-1573) and HeLa cells (CRL-1651) were purchased from the American Type Culture Collection and were tested for mycoplasma. HEK293 and HeLa cell cultures were maintained in 5% CO 2 at 37 °C in DMEM (Cellgro) supplemented with 10% FBS (Gibco), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Cellgro). Cultures were transfected using FuGENE-6 (Roche) according to the manufacturer's protocol. Transgene expression was evaluated 36-72 h after transfection by indirect
